News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BottomBuster Alert DD Post on APNS.OB (.06) Extremely Undervalued Biotech Play w/Major Partners (Eli Lilly, Takeda, & others) & Strong Financial Backing! Major Alzheimer's Conference this week to set opportunities in motion.
http://www.alz.org/icad/
Dinner Presentation by Lilly to discuss the clinical biomarker of APNS.OB
http://www.appliedneurosolutions.com/doc/APNS_8K_April_2008-Lilly-Milestone.doc
Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting
1:00p ET July 14, 2008 (Business Wire)
Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer's disease (AD) research and development program, including three on the two promising investigational therapies in the early stages of development, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago, July 26-31.
Pfizer will also host an analyst briefing at ICAD to review its neuroscience pipeline and platform on Monday, July 28. In addition, Pfizer will sponsor a satellite symposium, "Innovative Approaches to Alzheimer's Disease: Developing the Next Generation of Treatment," on Tuesday, July 29.
"With the expected huge increase in the incidence of Alzheimer's disease worldwide in the next 25 years, Pfizer's neuroscience team has made this devastating illness our highest priority," said Dr. Liam Ratcliffe, senior vice president and development head for Pfizer Neuroscience. "With new insights into the underlying causes of Alzheimer's discovered in only the past few years, our scientists are working to develop new medicines that improve memory and other cognitive function, and importantly halt or significantly slow the progression of the disease. We are also working on approaches that could lead to earlier and better diagnosis."
Pfizer's investigational compounds target multiple pathways to combat AD, beta amyloid, the harmful protein that builds up in the brains of AD patients; amyloid plaques, the sticky deposits made of beta amyloid fragments that impair the function of brain cells; chronic inflammation of neurons, and loss of function across the synapses (or gaps) between neurons.
Data from Pfizer to be presented at the meeting include:
-- Receptor for Advanced Glycation End-products (RAGE) Antagonist: Pfizer is in collaboration with TransTech Pharma to develop and commercialize a portfolio of RAGE modulators. RAGE is a cell-surface receptor that may play a key role in multiple aspects of AD. Targeting RAGE for Alzheimer's is a novel approach and Pfizer is pioneering this approach in the clinic. -- Initial Phase II data on the safety and tolerability of Pfizer's oral RAGE antagonist known as PF-04494700 will be presented by Dr. Marwan Sabbagh, FAAN, director of The Cleo Roberts Center of Clinical Research at the Sun Health Research Institute in Sun City, AZ, on Wednesday, July 30th at 12:30 p.m. CST. -- Preclinical data on the effect of PF-04494700 on chronic inflammation and buildup of amyloid plaques - two abnormal processes that are implicated in causing damage and death to brain cells in AD - will also be presented by Dr. Jeffrey Webster of TransTech Pharma on Monday, July 28th at 12:30 p.m. CST. -- Humanized Anti-Amyloid Monoclonal Antibody: Preclinical data on the effect of PF-04360365, Pfizer's investigational monoclonal antibody in Phase 1 trials, on beta amyloid levels in the brains of mice will be presented by Dr. Thomas Lanz, Senior Scientist at Pfizer, on Monday, July 28th at 12:30 p.m. CST. Monoclonal antibodies are designed to selectively target a specific protein, which, in the case of AD, is beta amyloid.
Additional Preclinical Research:Pfizer will also present data on a potential blood biomarker that could help in identifying patients with AD; two studies on the role of the brain's immune system in the formation of amyloid plaques; a potential method of using novel imaging and microscopic analysis to quantify AD neuropathology, and early research on an additional investigational Pfizer compound on the inhibition of an enzyme in the brain.
About Alzheimer's Disease
Alzheimer's disease is a progressive disorder characterized by the gradual loss of memory and a decline in cognitive ability; changes in behavior, and a loss in ability to carry out daily activities. It places a tremendous burden on patients, those caring for them, and healthcare systems, costing the U.S. Government more than $148 billion annually. Alzheimer's disease remains one of the world's most undiagnosed diseases, with only one-third of the world's approximately 18 million sufferers receiving treatment.
DISCLOSURE NOTICE: The information contained in this release is as of July 14, 2008. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about certain investigational compounds, including their potential benefits in treating Alzheimer's disease, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such compounds as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and in its reports on Form 10-Q and Form 8-K.
Applied NeuroSolutions to Offer P-Tau 231 Test for Use in Alzheimer's Disease Clinical Trials
Tuesday May 13, 9:30 am ET http://biz.yahoo.com/bw/080513/20080513005944.html?.v=1&printer=1
VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTC BB:APNS - News)(www.AppliedNeuroSolutions.com), a company focused on the development of products for the early diagnosis and treatment of Alzheimer’s disease (“AD”), today announced an initiative to provide its P-Tau 231 cerebrospinal fluid (CSF) test to companies undertaking AD clinical trials. Potential customers, which include pharmaceutical, biotechnology and imaging companies, may use the P-Tau 231 test to aid in screening patients for clinical trials and to track P-Tau 231 levels pre- and post-drug treatment. Applied NeuroSolutions has identified over 50 companies with 100 plus compounds in active clinical development for AD. Revenue generated from providing this service would help support the further development of Applied NeuroSolutions’s diagnostic pipeline, with a goal of delivering a serum-based test for the early diagnosis of AD.
The Company’s P-Tau 231 test has been extensively researched and has overall sensitivity and specificity of 85% to 95%. This is based on a broad range of testing by US and international academic researchers to differentiate patients diagnosed with AD from patients diagnosed with other forms of dementia and other relevant neurological diseases, including major depression, as well as age-matched healthy controls. The data generated from over 2,000 CSF samples have been published in 21 peer-reviewed articles in leading neurology and other scientific journals.
In addition, Applied NeuroSolutions, has to date used the P-Tau 231 test to analyze over 1,500 samples for leading global pharmaceutical companies and is now offering this service to additional customers in response to the growing number of clinical trials to develop better solutions for the increasing AD population. Given the substantial investment required to conduct clinical trials, collection of information provided by the P-Tau 231 test can offer a cost- effective tool to optimize companies’ AD drug development programs.
According to Dr. Mony de Leon, Professor of Psychiatry and Director Center for Brain Health at NYU School of Medicine “P-Tau 231 is now a validated biomarker of neurofibrillary-tangles, a hallmark pathology of Alzheimer’s disease. Among all of the potential AD biomarkers, P-Tau 231 has consistently been the most successful in the diagnosis of AD, not only in the differential diagnosis of Alzheimer’s disease in contrast to other dementias, but also in the very important early stages before the clinical manifestation of AD where the opportunity for therapeutic impact is greatest.”
Big close here!!! .08! 
nice volume too.
blocked? wtf? i dont know why. must be a mistake. i fix it now. happens sometimes. 
|
Followers
|
9
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
363
|
|
Created
|
04/22/05
|
Type
|
Free
|
| Moderators | |||
http://www.appliedneurosolutions.com/index.html
Applied NeuroSolutions, Inc. (APNS) is a development stage biopharmaceutical company focused on diagnostics and therapeutics for the treatment of Alzheimer’s Disease (AD).
Applied NeuroSolutions’ has a long-term agreement with Albert Einstein College of Medicine (AECOM) that grants APNS the exclusive licensing rights to commercialize Dr. Peter Davies’ neurodegenerative disease related discoveries. The technologies are based on the presence of an abnormal form of a protein present in the brains and cerebrospinal fluid (CSF) of AD patients. A specific chemical change in this protein, known as tau, results in an abnormal protein called ptau-231 (tau protein phosphorylated on amino acid 231). The presence of the ptau-231 protein leads to the development of abnormal structures (paired helical filaments and neurofibrillary tangles – the hallmark of Alzheimer’s disease) that contribute to nerve cell death. The correlation between excess amounts of the ptau-231 protein and AD supports the development of diagnostic tests, in vitro drug discovery systems and therapeutics aimed at preventing the formation of this protein and the accompanying neuron-destroying structures. The Company’s technology originated from Dr. Peter Davies, the Judith and Burton P. Resnick Professor of Alzheimer’s Disease Research at the Albert Einstein College of Medicine, and APNS’ scientific founder.
AD Diagnostic Test
Increased amounts of the altered tau protein (ptau-231) in cerebrospinal fluid (CSF) distinguish AD patients from those with other forms of cognitive impairment, providing an early diagnostic test and a method for following disease progression. Applied NeuroSolutions has developed an antibody-based test measuring the protein in the CSF of AD patients and is working on a second-stage blood serum-based test that is expected to be easier to perform and less expensive.
Currently there are no approved diagnostic tests to detect AD and follow its progression. Confirmation of diagnosis is performed through a series of behavioral measurements and brain scans. Definitive diagnosis can be made only from examination of postmortem brain tissue samples. Applied NeuroSolutions’ test would provide a significant breakthrough in supporting definitive early diagnosis.
Alzheimer’s Drug Discovery Platforms
The Company is working on a therapeutic program developed by Dr. Peter Davies based on the common pathway leading to the development of abnormal, destructive brain structures characteristic of AD. This screen can be used to identify drugs that interfere with that pathway, thereby preventing disease development.
Mouse Model for AD
Dr. Davies and the Nathan Kline Institute (NKI) have developed a transgenic mouse model of AD that exhibits Alzheimer-like pathology including accumulation of the abnormal form of tau (p-tau 231) and extensive neuronal death. These mice can be used to test for candidate drugs. The Company and NKI intend to market these models and several drug development companies have expressed interest in them.
Agreements with Pfizer, Novartis
Several major pharmaceutical and biotechnology companies have utilized Applied NeuroSolutions tools and technology to enhance their efforts to develop more effective drugs for Alzheimer's. In January 2003, the Company announced a Research Agreement with Pfizer, Inc. In November 2003, the Company also announced a Research Agreement with Novartis Pharmaceuticals Corporation.
Basis of Research
All of the Company's products and research tools are based upon a distinctive view of the cause and progression of Alzheimer’s disease developed over the past 25 years by Dr. Peter Davies and his colleagues at the Albert Einstein College of Medicine, where Dr. Davies currently serves as the Burton P. and Judith Resnick Professor of Alzheimer's Disease Research.
History
Applied NeuroSolutions was created from a reverse merger of Molecular Geriatrics Corporation into the public company Hemoxymed, Inc. on September 10, 2002. The management team comes from Molecular Geriatrics and has worked together as a group since 1993. The Company changed its name to Applied NeuroSolutions in October 2003 to reflect its focus upon the diagnosis and treatment of AD. The Company’s stock currently trades on the Over-the-Counter Bulletin Board (OTCBB) under the symbol APNS.OB.
The company's address is 50 Lakeview Parkway, Suite 111, Vernon Hills, Illinois, 60061. The telephone number is 847-573-8000 and the fax number is
847-573-8030.
Corporate Presentation http://www.appliedneurosolutions.com/pdf/APNS_Presentation_11_29_07.pdf
| The Company’s management team and board of directors include experienced scientists from both academic and pharmaceutical settings as well as senior executives with considerable experience in the development, management and commercialization of biotech and pharmaceutical products. Dr Peter Davies, the Company’s founding scientist is world renowned as an Alzheimer’s disease researcher. The Directors, executive officers, and certain key scientists and advisors of the Company are as follows: |
| Ellen R. Hoffing | Chairman of the Board of Directors, President and Chief Executive Officer |
| Robert S. Vaters | Director |
| Jay B. Langner | Director |
| Alan L. Heller | Director |
| David C. Tiemeier, Ph.D. | Director |
| Peter Davies, Ph.D. | Founding Scientist |
| David Ellison, CPA | Chief Financial Officer & Corporate Secretary |
| John F. DeBernardis, Ph.D. | Chief Scientific Officer |
For Further Information, Contact:
| Ellen Hoffing, President and CEO | Applied NeuroSolutions, Inc. |
| Email: | hoffing@appns.com |
| Telephone: | (847) 573-8000 |
| Fax: | (847) 573-8030 |
| Mailing Address: | 50 Lakeview Pkwy, Suite 111 Vernon Hills, IL 60061 |
| David Ellison, CFO | Applied NeuroSolutions, Inc. |
| Email: | ellison@appns.com |
| Telephone: | (847) 573-8000 |
| Fax: | (847) 573-8030 |
| Mailing Address: | 50 Lakeview Pkwy, Suite 111 Vernon Hills, IL 60061 |
Background
Alzheimer’s disease (AD) is an intractable, chronic and progressively incapacitating disease characterized by the degeneration and death of several types of neurons in certain regions of the brain. Patients affected by the disease initially suffer loss of memory, then a decline of intellectual abilities severe enough to interfere with work and activities of daily living, followed by severe dementia and, finally, death. This illness, currently affecting an estimated 4.5 million people in the United States, and approximately ten million people worldwide, is a leading cause of death behind cardiovascular disease and cancer. While the disease is most common in the elderly, affecting nearly 10% of people age 65 and older and up to 50% of people age 85 and older, it has been diagnosed in patients in their 40’s and 50’s.*
Alzheimer’s disease was first described in 1907 by Dr. Alois Alzheimer, a German psychiatrist who discovered large numbers of unusual microscopic deposits in the brain of a demented patient upon autopsy. These deposits, called amyloid plaques and neurofibrillary tangles, are highly insoluble protein aggregates that form in the brains of AD patients in particular regions, including those involved with memory and cognition. Generally, amyloid plaque is deposited on the surface of neurons, whereas neurofibrillary tangles are formed within neurons. The plaques and tangles are associated with degeneration and loss of neurons. The actual loss of neurons, as well as the impaired function of surviving neurons, is generally believed to be the key neuropathological contributors to the memory loss and dementia that characterizes Alzheimer’s disease.
Applied NeuroSolutions’s core technology in the AD field is based on the work of its founding scientist Dr. Peter Davies and his colleagues at the Albert Einstein College of Medicine. Much of Dr. Davies’ AD research has been involved within an abnormal form of a protein called tau that normally serves to stabilize microtubules, the transit system in nerve cells that directs molecules to their destinations. Excessive phosphorylation of tau prevents it from stabilizing microtubules. This internal neuronal damage leads to the development of the paired helical filaments and neurofibrillary tangles, which are contributing factors to the eventual death of the neurons related to Alzheimer’s disease, and is one of the hallmark pathologies associated with AD. There is a high correlation among the presence of neurofibrillary tangles and cognitive decline in AD.
* Alzheimer’s Association, February 2006
Diagnostic Program
Alzheimer’s disease, at present, can be conclusively diagnosed only by histological examination of the brain by biopsy or autopsy. The diagnosis of patients suspected of having AD is therefore typically made through a process of elimination, by conducting neurological and psychiatric examinations, extensive laboratory tests and a brain scan to rule out other conditions (such as stroke, brain tumor, or depression) with similar symptoms. The definitive AD predictive accuracy of such exams is generally in the range of 75-80%. Costs to patients for such testing currently runs anywhere from $1,000 - $4,000. A simple, predictive, accurate and cost effective diagnostic assay would therefore meet a tremendous medical need.
Applied NeuroSolutions has completed the development of a diagnostic assay utilizing cerebrospinal fluid (CSF). To date, the Company has completed numerous studies comprising in excess of 2,500 CSF samples utilizing this assay. These studies were designed to test the assay’s ability to differentiate patients diagnosed with AD from patients diagnosed with other forms of dementia and relevant neurological diseases, including major depression, as well as healthy controls. These studies have shown the ability of the assay to correctly identify the patients diagnosed with AD with an overall sensitivity and specificity in the 85% to 95% range. The studies have been published in peer reviewed scientific journals such as Neuroscience Letters, Archives of Neurology, Annals of Neurology, Archives of General Psychiatry, Journal of Internal Medicine, Neurobiology of Aging, Neurology, and American Journal of Psychiatry.
These data suggest that the phosphotau may represent an excellent biochemical marker for AD. It detects a characteristic feature of pathophysiology, may allow one to track disease progression and accurately discriminates between AD patients and neurological controls. Several pharmaceutical companies have utilized the Company’s CSF phosphotau assay as a biomarker in the clinical development of therapeutics to treat AD.
Therapeutic Program
The Company’s long-range goal is to discover and develop novel therapeutics to treat AD. Work is being conducted utilizing an in-vitro screen Dr. Davies has developed that could lead to the discovery of a therapeutic to stop the progression of Alzheimer’s disease. The basis for this screen is the discovery of a common pathway that leads to the development of both the neurofibrillary tangles and amyloid plaques.
The market potential for a drug to effectively treat Alzheimer’s disease is extremely large. Currently there are only five drugs approved in the U.S. to treat AD. Four of these drugs are cholinesterase inhibitors and one is an NMDA receptor antagonist. These drugs have limited beneficial effects in treating symptoms associated with AD and are not able to arrest the progression of the disease.
Transgenic Mice Model
To date, no accepted animal model for AD has been developed. However, recently Dr. Peter Davies, through collaboration with a researcher at Nathan Klein Institute (“NKI”), has produced a transgenic mouse that develops neurofibrillary tangles, one of the two hallmark pathologies of Alzheimer’s disease. The pathology in these mice is Alzheimer-like, with hyperphosphorylated tau accumulating in cell bodies and dendrites leading to the production of neurofibrillary tangles. In addition, these transgenic mice have exhibited extensive neuronal death, which accompanies the tau pathology. These new transgenic mice could be used for testing the efficacy of therapeutic compounds. Several pharmaceutical and biotechnology companies have expressed interest in acquiring access to these transgenic mice for testing their therapeutics. The Company and NKI are currently marketing these mice to researchers.
| |||
| | |||
Share Structure
| Shares Outstanding: | 130.19M |
| Float: | N/A |
| % Held by Insiders: | 30.19% |
| % Held by Institutions: | 1.40% |
Balance Sheet
Total Cash (mrq): 2.56M
Total Cash Per Share (mrq): 0.02 Total Debt (mrq): 0 Total Debt/Equity (mrq): N/A Current Ratio (mrq): 3.042
SEC Filings
http://finance.yahoo.com/q/sec?s=APNS.OB
Recent Headlines
http://finance.yahoo.com/q/h?s=APNS.OB
(2 Year Chart)
Daily Chart
[chart]stockcharts.com/c-sc/sc?s=APNS&p=D&b=5&g=0&i=p70666451736&a=145000874&r=9732[/chart]
